Search Within

Malin Lisa Hultcrantz

  1. "2021"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (13)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (30)
  2. Department of Medicine (30)
  3. Hematologic Malignancies, Division of (30)
  4. Myeloma (30)
  5. Sloan Kettering Institute Postdocs (30)
  6. Hematologic Malignancies Research (17)

More Groups

People
  1. Alexander Lesokhin (15)
  2. Sham Mailankody (14)
  3. Urvi Shah (14)
  4. Hani Hassoun (13)
  5. Neha Korde (13)
  6. Carlyn Rose Tan (12)

More People

Years
  1. 2021 (30)
Publications
  1. Blood (11)
  2. Clinical Lymphoma, Myeloma and Leukemia (4)
  3. Blood Cancer Journal (2)
  4. European Journal of Haematology (2)
  5. Nature Communications (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Nature Publishing Group (5)
  3. Elsevier Inc. (4)
  4. American Association for Cancer Research (2)
  5. Elsevier Science, Inc. (2)
  6. John Wiley & Sons (2)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevalence of smoldering multiple myeloma: Results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Thorsteinsdottir, S.; Gislason, G. K.; Aspelund, T.; Rögnvaldsson, S.; Oskarsson, J. T. T.; Petirsdottir, I.; Sigurdsson, J. K.; Sigurdardottir, G. A.; Thordardottir, A. R.; Vidarsson, B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Estimating selection bias in previous monoclonal gammopathy of undetermined significance research - the importance of screening: Results from the population-based screening study Iceland screens, treats or prevents multiple myeloma (iStopMM)
    Meeting Abstract

    Sigurbergsdóttir, A. Ý.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance and COVID-19: Results from the population-based Iceland screens treats or prevents multiple myeloma study (iStopMM)
    Meeting Abstract

    Rögnvaldsson, S; Eythorsson, E.; Thorsteinsdottir, S.; Vidarsson, B.; Onudarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Horsteinsdottir, I.; Olafsson, I.; Runolfsdottir, H. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Defining new reference intervals for serum free light chains in individuals with reduced kidney function: Results of the population- based on Iceland screens treats or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Long, T. E.; Indridason, O. S.; Palsson, R.; Rögnvaldsson, S.; Love, T. J.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial. First results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Kristinsson, S. Y.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Reed, E. R.; Oskarsson, J. T. T.; Petursdottir, I.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Brunner, J.; Byrne, J.; Eliason, L.; more...
    Blood (2021)

    Fulltext@MSK | Save